Exicure, Inc. (XCUR) AI Stock Analysis
XCUR AI stock analysis summary
AI ResearchExicure, Inc. (XCUR) is a biotechnology company developing therapies based on its proprietary spherical nucleic acid technology. The company recorded $0 in trailing twelve-month revenue, posted a net loss of -$9.7M in FY2024, and held $1.7M in cash as of June 30, 2026. The stock closed at $1.12, reflecting a 1-year return of -77.1%.
- Market cap
- $7.3M
- Revenue (TTM)
- $0
- P/E
- —
- 1Y return
- -77.1% S&P 500 16.8%
- Avg. target
- $2.00 78.6% vs last close
Bull case
- The mean analyst price target of $2.00 stands 78.6% above the last closing price of $1.12.
- Exicure generated a 5-year revenue CAGR of 33.5% between FY2018 and FY2024.
- The company recorded quarterly revenue growth of 928.0% year-over-year in the period ended June 30, 2026.
Bear case
- Exicure recorded $0 in trailing twelve-month revenue and a net loss of -$9.7M in FY2024.
- The company's liquidity remained constrained with a current ratio of 0.56 and cash and short-term investments of $1.7M as of June 30, 2026.
- Existing shareholders faced dilution as the company increased its share count by 115.8% over 5 years.
What Exicure does
Exicure, Inc. is a biotechnology company based in Chicago, Illinois, focused on developing therapies using its proprietary spherical nucleic acid (SNA) technology. Its platform is designed to target neurological disorders and hair loss. The company's lead preclinical candidate, SCN9A, is being evaluated for the treatment of neuropathic and chronic pain. Exicure has entered into a strategic agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders. Additionally, it has partnered with Ipsen S.A. to advance spherical nucleic acids targeting Huntington's disease and Angelman syndrome. Founded in 2011, the company operates with 1 employee.
Growth and profitability
Exicure's annual revenue reached $28.8M in FY2022 before falling 98.3% to $500,000 in FY2024. In FY2024, its operating margin was -2446.4%, and its net loss was -$9.7M, resulting in an EPS of -$2.44. Research and development expenses declined to $0 in FY2024 from $19.8M in FY2022. For the trailing twelve months ended June 30, 2026, revenue stood at $0 and EPS was -$1.31, although quarterly revenue grew 928.0% year-over-year in the quarter ended June 30, 2026. Between FY2018 and FY2024, the company recorded a 5-year revenue CAGR of 33.5%.
Balance sheet and cash flow
As of June 30, 2026, Exicure held cash and short-term investments of $1.7M and total assets of $11.4M. Shareholders' equity stood at $977,000, and its current ratio was 0.56. During FY2024, operating cash flow was -$2.9M, which matched free cash flow of -$2.9M. The company recorded capital expenditures of $1,000 in FY2025. Over the past 5 years, Exicure's share count increased by 115.8%.
Valuation and performance
At a closing price of $1.12, Exicure had a market capitalization of $7.3M and an enterprise value of $5.7M. The stock trades at a price-to-sales multiple of 13.6x and an enterprise value-to-revenue multiple of 27.2x, compared to a median price-to-sales multiple of 4.1x for its US-listed Healthcare peers. Its price-to-book ratio is 8.4x. Over the past year, Exicure's shares declined 77.1%, while the S&P 500 (SPY) gained 16.8%. Over a 5-year period, the stock dropped 99.4% against an 83.0% gain for the index.
What analysts expect
Wall Street analysts have established a mean price target of $2.00 for Exicure, which represents a 78.6% premium over its last closing price of $1.12. Over the prior four quarters, the company beat consensus EPS estimates 1 time. Exicure is scheduled to report its next earnings on November 6, 2026.
Key risks and what to watch
- Cash and short-term investments totaled $1.7M as of June 30, 2026, alongside negative operating cash flow of -$2.9M in FY2024.
- The stock displays elevated market sensitivity with a beta of 3.64 and has lost 77.1% over the past year.
- Research and development spending dropped to $0 in FY2024 while the company operates with 1 employee.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this XCUR AI stock analysis
This page is an AI-written research summary of Exicure, Inc. (XCUR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: XCUR income statement, XCUR balance sheet, XCUR key metrics, XCUR chart. See the XCUR stock overview for the latest quote and news.
XCUR AI stock analysis FAQ
What is Exicure's cash position?
As of June 30, 2026, Exicure held $1.7M in cash and short-term investments, with total assets of $11.4M and a current ratio of 0.56.
What is the consensus analyst target for XCUR stock?
The mean analyst price target for XCUR is $2.00, which is 78.6% higher than its last closing price of $1.12.
How has XCUR performed against the broader market?
Over the past year, XCUR shares fell 77.1% while the S&P 500 gained 16.8%. Over five years, the stock dropped 99.4% compared to an 83.0% gain for the S&P 500.
When does Exicure report its next quarterly earnings?
Exicure's next earnings release date is scheduled for November 6, 2026.